# KEYNOTE-365 (NCT02861573)

> Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02861573
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Metastatic Castration-Resistant Prostate Cancer
- Interventions: Pembrolizumab 200 mg; Olaparib 400 mg; Docetaxel 75 mg/m^2; Prednisone 5 mg; Enzalutamide 160 mg; Dexamethasone 8 mg; Olaparib 300 mg; Abiraterone acetate 1000 mg; Lenvatinib; Pembrolizumab/Vibostolimab coformulation; Carboplatin; Etoposide; Belzutifan 120mg
- Enrollment: 1200
- Primary outcome: Percentage of Participants With a Decrease of ≥50% in Prostatic Specific Antigen (PSA)
- Primary outcome: Number of Participants with Adverse Events (AEs)
- Primary outcome: Number of Participants Discontinuing Study Drug Due to AEs
- Primary outcome: Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 10
- Podcasts: 7
- YouTube: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=keynote-365-nct02861573

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02861573", "email": "<work email>"}; the inbox owner confirms by the emailed link.